• An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)

  • Feb 20 2025
  • Durée : 44 min
  • Podcast

An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)

  • Résumé

  • In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was appointed to lead the organization following the retirement of Dr. Steven Pearson. Sarah outlines her vision for ICER and the priorities for strengthening the framework and collaboration to achieve their mission of evaluating the comparative effectiveness of new medicines. Sarah also discusses ICER’s efforts to expand patient engagement and the evaluation of payers to ensure fair access to medicine.

    • Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)
    • Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER)
    • Barriers to Fair Access Report
    • Gross-to-Net Bubble
    • Pharmacy Benefit Managers (PBMs)
    • Humira biosimilars
    • Institute for Clinical and Economic Review (ICER)
    • 340B Drug Pricing Program

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    Afficher plus Afficher moins
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

    Ce que les auditeurs disent de An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)

    Moyenne des évaluations utilisateurs. Seuls les utilisateurs ayant écouté le titre peuvent laisser une évaluation.

    Commentaires - Veuillez sélectionner les onglets ci-dessous pour changer la provenance des commentaires.

    Il n'y a pas encore de critique disponible pour ce titre.